2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original Research
2011
Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated Adenocarcinoma
Farris AB, Demicco EG, Le LP, Finberg KE, Miller J, Mandal R, Fukuoka J, Cohen C, Gaissert HA, Zukerberg LR, Lauwers GY, Iafrate AJ, Mino-Kenudson M. Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated Adenocarcinoma. The American Journal Of Surgical Pathology 2011, 35: 647-655. PMID: 21422910, DOI: 10.1097/pas.0b013e31820f18a2.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesSignet ring cellsMicrosatellite instabilityBarrett's esophagusSporadic microsatellite unstable colorectal cancersEpstein-Barr virus-encoded RNARing cellsHigh-level microsatellite instabilityOlder patient ageMicrosatellite-unstable colorectal cancersLack of benefitVirus-encoded RNAUnstable colorectal cancersHMLH1 promoter methylationAdjuvant therapyLymphovascular invasionOverall survivalPatient ageClinicopathologic featuresStudy cohortConventional adenocarcinomaMucinous componentColorectal cancerMean ageMedullary carcinoma